Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments

BACKGROUND: Multiple sclerosis (MS) is a highly debilitating immune mediated disorder and the second most common cause of neurological disability in young and middle-aged adults. Iran is amongst high MS prevalence countries (50/100,000). Economic burden of MS is a topic of important deliberation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikfar, Shekoufeh, Kebriaeezadeh, Abbas, Dinarvand, Rassoul, Abdollahi, Mohammad, Sahraian, Mohammad-Ali, Henry, David, Akbari Sari, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698128/
https://www.ncbi.nlm.nih.gov/pubmed/23800250
http://dx.doi.org/10.1186/2008-2231-21-50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698128/
https://www.ncbi.nlm.nih.gov/pubmed/23800250
http://dx.doi.org/10.1186/2008-2231-21-50

Ejemplares similares